A Prospective, Multicenter Phase 2/3 Study to Assess the Efficacy and Safety of Mangaciclanol in Adult Patients With Known or Highly Suspected Lesions Referred for Contrast-Enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) or Body (LUMINA)

This is an operationally combined Phase 2/3 study, which will be conducted and evaluated in 2 distinct parts:
* Phase 2: Prospective, adaptive, multicenter, non-randomized, single-blind, dose-finding, including participants with known or highly suspected lesions of the CNS. The aim of the Phase 2 part is to identify an optimized dose of mangaciclanol for the Phase 3 part of the study.
* Phase 3: Prospective, multicenter, randomized, controlled, single-blind, cross-over, including participants with known or highly suspected lesions of the CNS or body. The aim of the Phase 3 part is to further evaluate the efficacy and safety of mangaciclanol-enhanced MRI for the detection and characterization of lesions of the CNS or body.
The investigational medicinal products (IMPs) used during the trial are mangaciclanol and gadobutrol (comparator IMP).
Primary and key secondary efficacy analyses will be based on independent central blinded image evaluation (BIE), and Phase 2 data will be analyzed prior to commencement of Phase 3.

Start Date01 Apr 2026

Sponsor / Collaborator

GE Healthcare Technologies, Inc.

100 Clinical Results associated with Gadobutrol

100 Translational Medicine associated with Gadobutrol

100 Patents (Medical) associated with Gadobutrol

768

Literatures (Medical) associated with Gadobutrol

01 Jul 2026·JOURNAL OF MAGNETIC RESONANCE IMAGING

T2 ‐Weighted T1 Mapping and Automated Segmentation of CSF : Assessment of Solute Gradients in the Healthy Brain

Article

Author: Lian, Sofie Lysholm ; Riseth, Jørgen ; Løvland, Grethe ; Mardal, Kent‐André ; Emblem, Kyrre Eeg ; Svensson, Siri Fløgstad ; Nordengen, Kaja ; Ringstad, Geir ; Storås, Tryggve Holck ; Mossige, Ingrid

ABSTRACT:

Background:

Cerebrospinal fluid (CSF) serves as a medium for nutrient delivery and waste clearance. The T1 relaxation rate, R1, can be used to measure the concentration of intrinsic solutes and extrinsic contrast agents.

Purpose:

To implement a method for R1 mapping and segmentation of CSF and to use this method to explore how R1 of CSF relates to protein content and gadobutrol after intrathecal administration.

Study Type:

Prospective cohort study, complemented by phantom analysis.

Population:

Ten healthy control subjects (mean age 65.5 ± 4.4 years, range 57–72 years; five males and five females) and protein‐ and gadobutrol‐gradient phantom.

Field Strength/Sequence:

3 T Philips Ingenia scanner; 3D T2W mixed inversion recovery spin‐echo (T2W‐mixed IRSE) sequence and 3D T1W turbo field echo (3D T1W‐TFE).

Assessment:

R1 maps were calculated by combining IR and SE data. An automated segmentation method derived from FreeSurfer employed SE data for CSF segmentation and T1W‐TFE for anatomical reference. CSF was collected by lumbar puncture for protein measurements, and 0.25 mmol gadobutrol was injected intrathecally. Post‐contrast assessments were performed at 3, 24, 48, and 72 h.

Statistical Tests:

One‐way ANOVA, followed by a post hoc Tukey HSD test, and simple and multiple linear regression analysis; significance level of 0.05.

Results:

R1 of ventricular CSF 0.216 ± 0.001 s −1 was significantly lower than that surrounding the cerebellum 0.225 ± 0.001 and cerebrum 0.228 ± 0.002 and correlated with lumbar protein concentration ( R2 = 0.56). Peak gadobutrol concentrations were 101 ± 84 μM in ventricles, 185 ± 89 μM in cerebellar SAS and 166 ± 91 μM in cerebral SAS. Corresponding concentrations were 6 ± 4, 17 ± 8, and 37 ± 18 μM at 72 h.

Data Conclusion:

Intrinsic R1 of CSF in the subarachnoid space correlated with protein content. Intracranial CSF enrichment after intrathecal administration of gadobutrol showed a large variation among healthy volunteers.

Evidence Level:

Technical Efficacy:

01 Jul 2026·AMERICAN JOURNAL OF NEURORADIOLOGY

Gadolinium-Enhanced Portable Ultra-Low-Field MRI for Evaluating Various Intracranial Pathologies

Article

Author: Yi, June ; Chittiboina, Prashant ; Horovitz, Silvina G ; Kazimuddin, Habeeb F ; Reich, Daniel S ; Pathakamuri, Ajay ; Soldatos, Ariane ; Brown, Desmond A ; Latour, Lawrence L ; Turtzo, L Christine

Portable ultra-low-field (pULF) MRI scanners, operating at magnetic fields below 100 mT, are broadening MRI accessibility. Despite the widespread use of contrast agents in clinical imaging, the efficacy of pULF-MRI in providing valid diagnostic information remains largely unexplored. This study evaluated the ability of pULF-MRI to detect diagnostically useful contrast-enhancement patterns compared with 3T MRI. We studied 5 cases representing a range of neurologic conditions: meningiomas in a patient with neurofibromatosis type 2, an incidental meningioma, a CNS mycobacterial infection, an oligodendroglioma repeat resection, and a chronic subdural hematoma. Imaging was performed following administration of gadoteridol, gadobutrol, or gadopiclenol, and enhancement patterns were qualitatively compared across matched slices. Postcontrast enhancement was visible on pULF-MR images in all cases and corresponded to 3T findings, though there were limitations in enhancement of calcified, small, or heterogeneously enhancing tissues due to several factors such as partial volume effects, SNR, image resolution, or some combination thereof. Our findings demonstrate that pULF-MRI can depict diagnostically meaningful gadolinium enhancement across multiple pathologies, establishing the feasibility and potential clinical utility of contrast-based neuroimaging at pULF. Further selection and validation of appropriate use cases can improve neurologic health outcomes in settings in which access to standard MRI is limited or contraindicated.

01 Jun 2026·MAGNETIC RESONANCE IN MEDICINE

Relaxivity of Gadobutrol and Gadoteric Acid in Cerebrospinal Fluid at 3 T

Article

Author: Anders Eklund ; Sofia Behndig ; Anders Garpebring ; Anders Wåhlin ; Daniel Dahlgren Lindström ; Jan Malm

ABSTRACT:

Purpose:

The aim was to estimate T1 relaxivity of gadobutrol and gadoteric acid in cerebrospinal fluid (CSF) at 3T, to support research on CSF‐flow and the glymphatic system in humans utilizing T1 mapping after intrathecal injection.

Methods:

Using a phantom, relaxivity was estimated for gadobutrol and gadoteric acid in lumbar CSF and an isotonic solution. All samples were scanned simultaneously using the variable flip angle method with B1 correction, repeated six times on one 3T scanner, and once on a second 3T scanner. Difference in relaxivity between CSF and the isotonic solution were evaluated from the repeated measurements.

Results:

There was a significant difference in relaxivity between CSF and the isotonic solution for both gadobutrol and gadoteric acid. The relaxivity for gadobutrol for the respective scanners was estimated to 3.02 ± 0.09 vs. 3.63 L mmol −1 s −1 in CSF and 2.35 ± 0.05 vs. 2.74 L mmol −1 s −1 in isotonic solution. For gadoteric acid, corresponding results were 2.47 ± 0.02 vs. 2.91 L mmol −1 s −1 in CSF and 2.37 ± 0.03 vs. 2.8 L mmol −1 s −1 in isotonic solution. Between the scanners, there was a high correlation ( R2 0.998) but an 18% scaling difference in the T1 relaxation rates and corresponding relaxivities.

Conclusions:

The relaxivity was higher in CSF than in the isotonic solution, particularly for gadobutrol. Systematic differences in relaxivity between scanners may potentially be corrected using a scaling factor derived from the T1 time of baseline CSF. For CSF studies using T1 mapping with a gadolinium‐based contrast agent, we recommend using a CSF‐specific relaxivity constant.

News (Medical) associated with Gadobutrol

23 Apr 2026

·www.businesswire.com

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents

CHALFONT ST GILES, England--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use in adults and pediatric patients aged 2 years and older with MRI to detect and visualize lesions with abnormal vascularity in the central nervous system and the body. FDA Fast Track designation expedites the review of new therapeutics and medical imaging agents that have the potential to address significant unmet patient needs. MRI contrast agents enhance the visualization of abnormal structures or lesions during imaging procedures and help clinicians better distinguish between healthy and diseased tissue. Mangaciclanol is intended for general-purpose MR imaging and demonstrates comparable relaxivity (the ability to enhance signal intensity) to market-leading gadolinium-based agent, gadobutrol, with early clinical images suggesting similar diagnostic capability. Unlike gadolinium, which is a rare-earth metal, manganese is present in our food, and is an endogenous element, naturally occurring and autoregulated in the body. The macrocyclic ‘cage-like’ structure of mangaciclanol lessens the possibility of retention. Approximately one-third of global MRI procedures require a contrast agent for effective diagnosis,1 with around 65 million gadolinium contrast enhanced procedures globally each year.2 As a rare-earth element, gadolinium supply is largely dependent on mining and processing infrastructure in China. Manganese, however, is abundantly available from multiple countries, including South Africa, Australia and Gabon, reducing the risk of supply challenges impacting patient care. Furthermore, as manganese is naturally found in water sources, mangaciclanol could also reduce environmental concerns associated with post-patient excreted contrast media in groundwater. Dr Jit Saini, Chief Medical Officer, Pharmacutical Diagnostics, GE HealthCare, said, “Existing gadolinium-based contrast agents carry safety language associated with gadolinium retention. In comparison, mangaciclanol could offer an alternative for broad patient groups, including vulnerable patients and those requiring multiple scans, while still offering similar diagnostic performance. The FDA Fast Track designation recognizes the potential significance of mangaciclanol and aligns with our focus on advancing its development for patients.” “As demand for diagnostic imaging continues to rise, we continue to advance our imaging agent pipeline to better meet the needs of patients,” said Peter Arduini, President and CEO, GE HealthCare. “This clinical milestone builds on GE HealthCare’s leadership in contrast media, as mangaciclanol has the potential to transform the MR imaging market and strengthen the resiliency of its supply chain.” Phase 1 results for mangaciclanol showed the investigational agent was well tolerated in a first in human trial with no serious adverse events, no dose limiting toxicities, nor clinically relevant findings reported. GE HealthCare’s Pharmaceutical Diagnostics unit is a global leader in imaging agents used to support 140 million patient procedures per year globally, equivalent to four procedures every second. For more than 40 years, GE HealthCare contrast media has been routinely used across MRI, X-ray/CT and ultrasound to enhance clinical images and support diagnosis. Mangaciclanol is in clinical development and currently not approved for use. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™. Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives. 1 Contrast Agents of Magnetic Resonance Imaging and Future Perspective. Nanomaterials. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10343825/ [europepmc.org] 2 Recent Developments and Future Perspectives in Magnetic Resonance Imaging and Computed Tomography Contrast Media. Frontiers in Radiology. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12871431/

Clinical ResultFast TrackPhase 1

28 Jan 2026

·www.biospace.com

The European Commission extended the Marketing Authorisation for Vueway® (gadopiclenol) in the European Union for use in pediatric patients under 2 years of age

Expanded EU approval reflects positive benefit-risk ratio of Vueway ® in children from birth MILAN , Jan. 27, 2026 /PRNewswire/ -- Bracco Imaging S.p.A., a global leader in diagnostic imaging, announces that on January 23, 2026, the European Commission (EC) amended the Marketing Authorisation for Vueway ® (gadopiclenol) in the European Union (EU), extending its approved indications to pediatric patients below 2 years of age. The extension granted by the EC followed the relevant positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and the recommendation sent by EMA to the EC. (1) Vueway ® (gadopiclenol) is a novel macrocyclic gadolinium-based contrast agent (GBCA) approved in 36 countries and used to provide contrast enhancement in Magnetic Resonance Imaging (MRI) examinations, thus helping doctors find certain pathologies in patients in whom this would not be possible otherwise. (2) In the European Union (EU), Vueway ® was approved in December 2023 for its use in adults and children aged 2 years and older for contrast-enhanced MRI to improve the detection and visualization of pathologies with disruption of the blood-brain-barrier (BBB) and/or abnormal vascularity of the brain, spine, and associated tissues of the central nervous system, as well as contrast-enhanced MRI of the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system. (3) On 11 December 2025, the CHMP adopted in EU a positive opinion for the extension of the approved indications of Vueway ® to infants and young children, including neonates, reinforcing the established safety and diagnostic performance of this new GBCA. (1) Vueway ® (gadopiclenol) is a highly stable, macrocyclic GBCA with the highest values of longitudinal relaxivity (r1) among all the currently approved GBCAs. (4) Large, multicenter clinical studies have shown that Vueway ® delivers comparable diagnostic efficacy at half the gadolinium dose of gadobutrol (5) , a GBCA widely used in clinical practice across the world. Lower-dose imaging offers the important clinical benefit of reducing exposure of patients to gadolinium. (6) "The ability to reduce exposure to gadolinium without affecting the diagnostic performance of MRI examinations is important for all patients receiving GBCAs, " said Alberto Spinazzi, Chief Medical & Regulatory Officer, Bracco Group. "This is particularly important when GBCAs are used in special patient populations, such as neonates, infants and toddlers, whose brains and body tissues are still maturing, and potential long-term effects of retained gadolinium are still unknown. Therefore, this approval on the extension of the use of Vueway ® from birth addresses a critical need." The positive CHMP opinion, the EMA recommendation, and the final EC approval were based on the results from study GDX-44-015 (study information and results are available here ). About gadolinium-based contrast agents Gadolinium-based contrast agents (GBCAs) are widely and routinely used to enhance the diagnostic performance of magnetic resonance imaging (MRI) examinations. Gadolinium is a rare earth metal that has unique magnetic properties that make it useful for the use in MRI imaging. About Bracco Imaging Bracco Imaging is a global leader in diagnostic imaging, dedicated to improving people's lives by shaping the future of prevention and precision medicine. With a strong passion for innovation, the company develops and provides a broad portfolio of pharmaceutical products for diagnostic imaging: contrast agents for X-ray, Computed Tomography (CT), and Magnetic Resonance Imaging (MRI), as well microbubbles for Contrast Enhanced Ultrasound (CEUS), and Molecular Imaging through radioactive tracers and novel PET imaging agents, alongside specialized medical devices and related services. The company is committed to advancing radiology by sharing knowledge to cultivate future thought leaders, linking today's practice with tomorrow's progress. Since 1927, Bracco Imaging has grown to more than 3,800 employees and now supports patients and radiology professionals in over 100 countries. Discover Bracco Imaging at . The Guerbet and Bracco Imaging collaboration Bracco Imaging and Guerbet in December 2021 entered a worldwide collaboration on Gadopiclenol manufacturing and research and development activities. Gadopiclenol will be commercialized independently under separate brands. Both Guerbet and Bracco Imaging each own valuable intellectual property on Gadopiclenol. Furthermore, after an agreed transition period when Guerbet manufactures Gadopiclenol for both Guerbet and Bracco, both companies will manufacture the Gadopiclenol active ingredient and finished product. The strategic collaboration is expected to accelerate access to Gadopiclenol and deliver innovation, as well as better care to patients and caregivers alike. Media Contact: Bracco Press Contact: Carolina Bargoni Bracco Imaging, Communications Director Carolina.bargoni@bracco.com References CHMP post-authorisation summary of positive opinion for Vueway (EMAVR0000249008). Available at: . Accessed on December 17, 2025. Vueway® (gadopiclenol). Overview. Available at: . Accessed on December 17, 2025. Vueway® (gadopiclenol). Summary of Product Characteristics. Available at : . Accessed on December 17, 2025. Robic C, Port M, Rousseaux O, Louguet S, Fretellier N, Catoen S, Factor C, Le Greneur S, Medina C, Bourrinet P, Raynal I, Idée JM, Corot C. Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity. Invest Radiol 2019; 54(8):475-484. Hao J, Pitrou C, Bourrinet P. A Comprehensive Overview of the Efficacy and Safety of Gadopiclenol: A New Contrast Agent for MRI of the CNS and Body. Invest Radiol 2024; 59(2):124-130. Kanal E, Maki JH, Schramm P, Marti-Bonmati L. Evolving Characteristics of Gadolinium-Based Contrast Agents for MR Imaging: A Systematic Review of the Importance of Relaxivity. J Magn Reson Imaging 2025; 61(1):52-69. SOURCE Bracco Group

Drug Approval

15 Sep 2024

·www.pharmaindustrial-india.com

Zydus Signs Licensing and Supply Agreement with Viwit Pharmaceuticals

Zydus Lifesciences Ltd. has announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, has signed an exclusive licensing and supply agreement with Viwit Pharmaceuticals (Viwit) for gadobutrol injection (generic version of GADAVISTTM) and gadoterate meglumine injection (generic version of DOTAREM) for the US market. As per the terms of the agreement, Viwit will be responsible for ANDA submission, manufacturing and supplying the generic versions of GADAVISTTM and DOTAREM, following the receipt of requisite regulatory approval. Zydus will exclusively market, distribute, and sell these products in the US market. Both the products are Gadolinium-based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus' injectable portfolio for the US market. The total addressable market opportunity for gadobutrol injection is estimated at USD 120 million and for gadoterate meglumine injection at USD 117 million in the US market. Zydus Lifesciences Ltd., with an overarching purpose of empowering people with the freedom to live healthier and more fulfilled lives, is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group has a significant presence in cancer-related therapies and offers a wide range of solutions with cytotoxic, supportive & targeted drugs. The group employs over 27,000 people worldwide, including 1,400 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives.

License out/in

100 Deals associated with Gadobutrol

External Link

KEGG	Wiki	ATC	Drug Bank
D07420	Gadobutrol	V08CA09	DB06703

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Coronary Artery Disease	United States	Bayer HealthCare Pharmaceuticals, Inc.	12 Jul 2019
Coronary Artery Disease	United States	Bayer Healthcare LLC	12 Jul 2019
Aortic Diseases	United States	Bayer HealthCare Pharmaceuticals, Inc.	27 Apr 2016
Aortic Diseases	United States	Bayer Healthcare LLC	27 Apr 2016
Breast Diseases	United States	Bayer Healthcare LLC	29 Dec 2014
Breast Diseases	United States	Bayer HealthCare Pharmaceuticals, Inc.	29 Dec 2014
Central Nervous System Vascular Malformations	United States	Bayer Healthcare LLC	14 Mar 2011
Central Nervous System Vascular Malformations	United States	Bayer HealthCare Pharmaceuticals, Inc.	14 Mar 2011
Cerebrovascular Disorders	United States	Bayer HealthCare Pharmaceuticals, Inc.	14 Mar 2011
Cerebrovascular Disorders	United States	Bayer Healthcare LLC	14 Mar 2011
Contrast agents	Australia	Bayer Australia Ltd.	02 Dec 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Carotid Stenosis	Phase 3	United States	Bayer AG	12 May 2011
Carotid Stenosis	Phase 3	China	Bayer AG	12 May 2011
Carotid Stenosis	Phase 3	Argentina	Bayer AG	12 May 2011
Carotid Stenosis	Phase 3	Australia	Bayer AG	12 May 2011
Carotid Stenosis	Phase 3	Austria	Bayer AG	12 May 2011
Carotid Stenosis	Phase 3	Czechia	Bayer AG	12 May 2011
Carotid Stenosis	Phase 3	France	Bayer AG	12 May 2011
Carotid Stenosis	Phase 3	Germany	Bayer AG	12 May 2011
Carotid Stenosis	Phase 3	Italy	Bayer AG	12 May 2011
Carotid Stenosis	Phase 3	Poland	Bayer AG	12 May 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03602339 (LEADER-75, Pubmed \| AJR Am J Roentgenol)	Phase 4	-	141	Reduced Dose Gadobutrol	vzasvzzimq(zelfcoyhdv) = xlhsgorpwh cezmsqsjxj (kbarhymsng ) View more	Positive	16 Jun 2021
NCT03602339 (LEADER-75, Pubmed \| AJR Am J Roentgenol)	Phase 4	-	141	Standard Dose Gadoterate	vzasvzzimq(zelfcoyhdv) = jlgrgztkvo cezmsqsjxj (kbarhymsng ) View more	Positive	16 Jun 2021
NCT03602339 (LEADER-75 \| LEADER 75, CTgov)	Phase 4	-	157	Gadoterate (Gadoterate 0.1 mmol/kg BW)	atuufejsuc(kqneyioebp) = cpeyzatlak sguvqasabl (xxvtslzmqs, 0.252) View more	-	28 Apr 2021
NCT03602339 (LEADER-75 \| LEADER 75, CTgov)	Phase 4	-	157	Gadobutrol (Gadobutrol 0.075 mmol/kg BW)	atuufejsuc(kqneyioebp) = kwzvlkyxsy sguvqasabl (xxvtslzmqs, 0.201) View more	-	28 Apr 2021
NCT03404648 (CTgov)	Phase 3	Advanced Prostate Carcinoma \| Adenocarcinoma of prostate	19	PET/MR scanner+C-11 choline PET tracer+Gadobutrol	mkwruzhtvs(tmtyujjvkf) = twllepmytk zmdjyvtezr (mypwuxarav, 1.8) View more	-	08 Feb 2021
NCT01890434 (GadaCAD 2, CTgov)	Phase 3	Coronary Artery Disease	478	Gadobutrol (Gadavist, Gadovist, BAY86-4875)	qabhdnlimd = gbfbzvzjfb nhjkfapqrl (rtgftrsnmb, wgqnlnczdz - ldlydkfewv) View more	-	16 May 2018
NCT01890421 (GadaCAD 1, CTgov)	Phase 3	Coronary Artery Disease	426	Gadovist	pptofalpja = otjsbtjhlw nmwqiotast (ygfcwonyyi, kddsyptvoe - qbzscfmeqq) View more	-	16 May 2018
NCT01095081 (GARDIAN, Pubmed \| Eur Radiol) Manual	Not Applicable	Contrast agents	23,708	gadobutrol	anwkphnzuq(splixzqruf) = zandngohlz dirdjeonkx (yhaqmcnhha ) View more	Positive	01 Jan 2017
NCT02034708 (REMIND, CTgov)	Phase 4	Brain Cancer	279	Gadovist (Gadovist® (Reader 1))	uoljkeosas = vxvkzlljfm ruowicrysp (tvhrgokrpd, mjufaheyfk - shcdolawwo)	-	25 Oct 2016
NCT02034708 (REMIND, CTgov)	Phase 4	Brain Cancer	279	Dotarem (Dotarem® (Reader 1))	uoljkeosas = mvumuskmhs ruowicrysp (tvhrgokrpd, znjulwegny - kfvngcnjmt)	-	25 Oct 2016
NCT01104584 \| NCT01067976 (Pubmed \| Invest Radiol) Manual	Phase 3	Neoplasms	906	Gadobutrol	hrengqsqhi(syrqiwryxz) = the detection rate of malignant disease extent per patient, ranged from 80% to 89% for CE-BMRI and was significantly superior to unenhanced breast MRI alone (37%-73%) and to mammography alone (68%-73%) for all readers in both trials. bbqkaupopt (fughraofud )	Positive	01 Jul 2016
NCT01344460 (GRAMS, Biospace) Manual	Phase 3	Vascular Diseases	292	Gadobutrol	kebbrjcrad(lnmunsvzrj) = imfrnrlnbk pebpswcpxu (achylmyvsi ) View more	Positive	29 Apr 2016
NCT01490294 (CTgov)	Phase 2	Cardiovascular Diseases	232	Gadovist (Gadobutrol 0.01 mmol/kg BW (Gadavist, BAY86-4875))	sdffzvisoc = eacigiokoo dnldsupynz (mxecdcuyyd, sccuzerdwp - ncgnzvpxuk) View more	-	28 Jun 2012
NCT01490294 (CTgov)	Phase 2	Cardiovascular Diseases	232	Gadovist (Gadobutrol 0.025 mmol/kg BW (Gadavist, BAY86-4875))	sdffzvisoc = jfmepdymee dnldsupynz (mxecdcuyyd, deizuzqsct - xdgfofvmiv) View more	-	28 Jun 2012

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis